Evidence mapPaperPMID 39669784Full record

ArticleFrontiers in microbiology2024

Prevalence and antibiotic resistance profile of UTI-causing uropathogenic bacteria in diabetics and non-diabetics at the Maternity and Children Hospital in Jeddah, Saudi Arabia.

Peter F Farag, Hamzah O Albulushi, Mohammed H Eskembaji, Mohammad F Habash, Mohammed S Malki, Muayad S Albadrani, Ahmed M Hanafy

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Trends in Antibiotic Resistance ofPathogens (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peter F FaragDepartment of Microbiology, Faculty of Science, Ain Shams University, Cairo, Egypt.
Hamzah O AlbulushiLaboratory Department, Medical Center, Taibah University, Al-Madinah, Saudi Arabia.
Mohammed H EskembajiLaboratory Department, Medical Center, Taibah University, Al-Madinah, Saudi Arabia.
Mohammad F HabashDepartment of Oncology and Medical Histology Pathology, Medical Sciences College Taibah University, Al-Madinah, Saudi Arabia.
Mohammed S MalkiMicrobiology Laboratory, Maternity and Children Hospital, Jeddah, Saudi Arabia.
Muayad S AlbadraniDepartment of Family and Community Medicine and Medical Education, College of Medicine Taibah University, Al-Madinah, Saudi Arabia.
Ahmed M HanafyDepartment of Microbiology, Faculty of Science, Ain Shams University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: One of the most prevalent and recurrent infectious diseases that can range from moderate to fatal is urinary tract infection (UTI). Broad-spectrum antibiotics are the only management strategy for UTIs in ambulators and hospital stays. Due to the ongoing emergence of antibiotic resistance among uropathogens, there is a need for proper selection of antibiotics for empirical therapy against UTIs. This study aimed to compare the etiological profiles and antibiotic susceptibility patterns between diabetic and non-diabetic UTI female patients from the Maternity and Children Hospital in Jeddah, Saudi Arabia. Methods: Urine samples from different age categories of female UTI patients were collected from January 2021 to June 2023. The positive urine cultures with a single pathogen were selected and all bacterial isolates were identified by MALDI-TOF/MS system. Antibiotic susceptibility testing was done using VITEK-2. Our study included 2,245 female patients, of which 1825 (81%) were non-diabetic and 420 (19%) were diabetic. Results: The results showed a significant relationship ( Discussion: According to the results, we concluded that the UTI etiological profiles varied among different ages. Ciprofloxacin is a safe medication with optimal sensitivity that can be used to treat both gram-positive and gram-negative bacteria.

Indexed as

age categoriesantibiotic resistanceetiological profilesfemale patientsurinary tract infection

Identifiers

PMID39669784
PMCPMC11635965

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.